Table 2.
Association Between SHBG Levels and NAFLD
| Model 1a | Model 1a + Visceral Adiposity | Model 1a + Visceral Adiposity + HOMA-IR | ||||
|---|---|---|---|---|---|---|
| Odds Ratio (95% CI) | P | Odds Ratio (95% CI) | P | Odds Ratio (95% CI) | P | |
| Log2 (SHBG) | 0.38 (0.26–0.56) | <.001 | 0.50 (0.33–0.77) | .001 | 0.52 (0.34–0.80) | .003 |
| Log2 (TT) | 0.75 (0.53–1.07) | .12 | 0.87 (0.60–1.25) | .44 | 0.93 (0.63–1.36) | .70 |
| HIV infection | 0.93 (0.55–1.58) | .80 | 0.65 (0.37–1.15) | .14 | 0.61 (0.34–1.09) | .10 |
| VAT (per 10 mm2) | 1.07 (1.04–1.11) | <.001 | 1.05 (1.02–1.09) | .002 | ||
| Ln (HOMA-IR) | 1.91 (1.17–3.11) | .01 | ||||
| Age (per year) | 1.00 (0.96–1.04) | .82 | 0.97 (0.93–1.01) | .14 | 0.97 (0.93–1.01) | .13 |
| Black race | 0.26 (0.12–0.54) | <.001 | 0.42 (0.19–0.92) | .03 | 0.34 (0.15–0.77) | .01 |
| PNPLA3 non-CC | 1.81 (1.10–2.98) | .02 | 2.03 (1.20–3.41) | .01 | 2.17 (1.28–3.68) | .004 |
Bold formatting signifies statistical significance at P < .05.
Abbreviations: CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance; NAFLD, nonalcoholic fatty liver disease; SHBG, sex hormone–binding globulin; TT, total testosterone; VAT, visceral adipose tissue.
aAlso adjusted for MACS sites and test batch.